Acecainide HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329648

CAS#: 34118-92-8 (HCl)

Description: Acecainide, also known as N-acetylprocainamide and ASL 601, is the N-acetylated metabolite of procainamide. Acecainide is a Class III antiarrhythmic agent. It can be given either intravenously or orally, and is eliminated primarily by renal excretion.


Chemical Structure

img
Acecainide HCl
CAS# 34118-92-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 329648
Name: Acecainide HCl
CAS#: 34118-92-8 (HCl)
Chemical Formula: C15H24ClN3O2
Exact Mass:
Molecular Weight: 313.826
Elemental Analysis: C, 57.41; H, 7.71; Cl, 11.30; N, 13.39; O, 10.20

Price and Availability

Size Price Availability Quantity
100.0mg USD 750.0 2 Weeks
200.0mg USD 1250.0 2 Weeks
500.0mg USD 2150.0 2 Weeks
1.0g USD 3250.0 2 Weeks
2.0g USD 4850.0 2 Weeks
5.0g USD 6950.0 2 Weeks
Bulk inquiry

Related CAS #: 32795-44-1 (free base)    

Synonym: Acecainide; N-acetylprocainamide, ASL 601; ASL-601; ASL601.

IUPAC/Chemical Name: 4'-((2-(Diethylamino)ethyl)carbamoyl)acetanilide monohydrochloride

InChi Key: IYEWBJUCJHKLHD-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H23N3O2.ClH/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19;/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19);1H

SMILES Code: CC(NC1=CC=C(C(NCCN(CC)CC)=O)C=C1)=O.[H]Cl

Appearance: Light yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 313.826 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Harron DW, Brogden RN. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40. Review. PubMed PMID: 1693889.

2: Coyle JD, Boudoulas H, Lima JJ. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. Biopharm Drug Dispos. 1991 Nov;12(8):599-612. PubMed PMID: 1724922.

3: Ghosh SC, Ngiam JS, Seayad AM, Tuan DT, Chai CL, Chen A. Copper-catalyzed oxidative amidation of aldehydes with amine salts: synthesis of primary, secondary, and tertiary amides. J Org Chem. 2012 Sep 21;77(18):8007-15. Epub 2012 Aug 30. PubMed PMID: 22894712.

4: Carter JE, Dutcher JS, Carney DP, Klein LR, Black LA, Erhardt PW. Analysis of procainamide hydrochloride and acecainide hydrochloride in rat feed. J Pharm Sci. 1980 Dec;69(12):1439-40. PubMed PMID: 6162025.

5: Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol. 1980 Sep;46(3):463-8. PubMed PMID: 6158263.

6: Vyden JK. Acecainide for ventricular arrhythmias. JAMA. 1982 Feb 5;247(5):581. PubMed PMID: 6172606.

7: Sanna GP. New drugs in the management of ventricular arrhythmias. G Ital Cardiol. 1984 Oct;14(10):788-97. PubMed PMID: 6083894.

8: Bateman DN. Pharmacokinetics and metabolism of the benzamides. Adv Biochem Psychopharmacol. 1982;35:143-62. Review. PubMed PMID: 6183928.

9: Somberg J, Wynn J, Miura D, Torres V, Williams S, Keefe D. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia. Angiology. 1986 Dec;37(12 Pt 2):972-81. PubMed PMID: 2433972.

10: Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982 Oct 21;307(17):1080. PubMed PMID: 6181402.

11: Atkinson AJ Jr, Lertora JJ, Kushner W, Chao GC, Nevin MJ. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Clin Pharmacol Ther. 1983 May;33(5):565-76. PubMed PMID: 6188570.

12: Liu XQ, Huang SK. [Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. Zhongguo Yao Li Xue Bao. 1991 Jan;12(1):7-11. Chinese. PubMed PMID: 1719744.

13: Kabra PM, Chen SH, Marton LJ. Liquid-chromatographic determination of antidysrhythmic drugs: procainamide, lidocaine, quinidine, disopyramide, and propranolol. Ther Drug Monit. 1981;3(1):91-101. PubMed PMID: 7233493.

14: Meisner DJ, Carlson RJ, Gottlieb AJ. Thrombocytopenia following sustained-release procainamide. Arch Intern Med. 1985 Apr;145(4):700-2. PubMed PMID: 2580499.

15: Pirovino M, Karlaganis G, Galeazzi RL. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation]. Schweiz Med Wochenschr. 1980 Sep 27;110(39):1415-9. German. PubMed PMID: 6169144.

16: Karol MD, Goodrich S. Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution. Pharm Res. 1988 Jun;5(6):347-51. PubMed PMID: 2469080.

17: Piergies AA, Ruo TI, Jansyn EM, Belknap SM, Atkinson AJ Jr. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clin Pharmacol Ther. 1987 Jul;42(1):107-12. PubMed PMID: 2439251.

18: Boucher M, Dubray C, Paire M, Duchêne-Marullaz P. Comparative effects of procainamide and its N-acetylated metabolite in conscious dogs with atrioventricular block: plasma concentration-response relationships. J Cardiovasc Pharmacol. 1987 Nov;10(5):562-7. PubMed PMID: 2447406.

19: Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg MM. Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N Engl J Med. 1979 Dec 20;301(25):1382-5. PubMed PMID: 91972.

20: Ludden TM, Crawford MH, Kennedy GT. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias. Pharmacotherapy. 1985 Jan-Feb;5(1):11-5. PubMed PMID: 2580291.